Braveheart Bio has filed to raise up to $318.8 million in an initial public offering on Nasdaq, and a16z Bio + Health is the lead backer. For a firm with no approved drugs and a lead candidate still in Phase 2 trials, that’s a bold ask. What Braveheart actually doesBraveheart Bio is a clinical-stage biopharmaceutical company focused on hypertrophic cardiomyopathy, or HCM. Why crypto investors should pay attention to a heart drug IPOAndreessen Horowitz famously raised $4.5 billion for its fourth crypto fund in 2022, making it the largest crypto venture fund in history at the time. Any policy shifts there could affect not just Braveheart but the entire cohort of US biotechs relying on similar arrangements.